×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Brielle Urciuoli
While causes for pneumonia were varied – including bacteria (14 percent), virus (22 percent) and unspecified (64 percent) – the majority of children did not have immune deficiencies recorded at the time of their pneumonia diagnosis.
Brielle Urciuoli
Health care practitioners were surprised when they saw 10 cases of a very rare cancer in the New York City area. As it turned out, most of the patients weren't originally from New York.
William G. Wierda, M.D., Ph.D.
William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).
Nicole Lamanna, MD, reminds patients with chronic lymphocytic leukemia about current research efforts and new therapies that are helping to transform how CLL is managed. Additionally, Dr. Lamanna offers advice to newly diagnosed patients.
Nicole Lamanna, MD, highlights unmet needs in chronic lymphocytic leukemia and suggests techniques health care professionals and patients can use to improve care.
Nicole Lamanna, MD, explains what refractory disease in chronic lymphocytic leukemia means and remarks on the importance of clinical trials and the use of stem cell transplantation for appropriate patients in this setting.
Nicole Lamanna, MD, defines relapse in chronic lymphocytic leukemia and remarks on considerations for selecting treatment in this setting.
Nicole Lamanna, MD, discusses the treatment of chronic lymphocytic leukemia and remarks on the potential for treating certain patients with ibrutinib, a Bruton’s tyrosine kinase inhibitor.
Nicole Lamanna, MD, discusses chromosomal abnormalities in chronic lymphocytic leukemia and explains how they play a role when making treatment decisions.
Nicole Lamanna, MD, discusses the significance of the watch-and-wait approach early on in a diagnosis of chronic lymphocytic leukemia.